ADDEX THERAPEUTICS LTD INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unaudited Interim Condensed Consolidated Financial Statements Unaudited Interim Condensed Consolidated Balance Sheets as of

ADDEX THERAPEUTICS LTD

INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED

FINANCIAL STATEMENTS

Therapeutics Unaudited Interim Condensed Consolidated Financial Statements

Unaudited Interim Condensed Consolidated Balance

as of September 30, 2023, and December 31,

The accompanying notes form an integral part of

these consolidated financial statements.

Therapeutics Unaudited Interim Condensed Consolidated Financial Statements

Unaudited Interim Condensed Consolidated Statements

of Comprehensive Loss

for the three-month and nine-month periods

ended September 30, 2023 and 2022

The accompanying notes form an integral part of

these consolidated financial statements.

Therapeutics Unaudited Interim Condensed Consolidated Financial Statements

Unaudited Interim Condensed Consolidated Statements

of Changes in Equity

for the nine-month periods ended September 30,

The accompanying notes form an integral part of

these consolidated financial statements.

Therapeutics Unaudited Interim Condensed Consolidated Financial Statements

Unaudited Interim Condensed Consolidated Statements

of Changes in Equity

for the three-month period ended September 30,

The accompanying notes form an integral part of

these consolidated financial statements.

Therapeutics Unaudited Interim Condensed Consolidated Financial Statements

Unaudited Interim Condensed Consolidated Statements

of Changes in Equity

for the three-month period ended September 30,

The accompanying notes form an integral part of

these consolidated financial statements.

Therapeutics Unaudited Interim Condensed Consolidated Financial Statements

Unaudited Interim Condensed Consolidated Statements

for the nine-month periods ended September 30,

The accompanying notes form an integral part of

these consolidated financial statements.

Addex Therapeutics Unaudited Interim

Condensed Consolidated Financial Statements Notes

Unaudited Notes to the Interim Condensed Consolidated

Financial Statements

for the three-month and nine-month periods

ended September 30, 2023

(Amounts in Swiss francs)

1. General information

Addex Therapeutics Ltd (the "Company"),

formerly Addex Pharmaceuticals Ltd, and its subsidiaries (together, the "Group") are a clinical stage pharmaceutical group

applying its leading allosteric modulator drug discovery platform to discovery and development of small molecule pharmaceutical products,

with an initial focus on central nervous system disorders.

The Company is a Swiss stockholding corporation

domiciled c/o Addex Pharma SA, Chemin des Aulx 12, CH1228 Plan-les-Ouates, Geneva, Switzerland and the parent company of Addex Pharma

SA, Addex Pharmaceuticals France SAS and Addex Pharmaceuticals Inc. Its registered shares are traded at the SIX, Swiss Exchange, under

the ticker symbol ADXN. On January 29, 2020, the Group listed on the Nasdaq Stock Market, American Depositary Shares (ADSs) under

the symbol "ADXN", without a new issuance of securities. ADSs represents shares that continue to be admitted to trading on

These interim condensed consolidated financial

statements have been approved for issuance by the Board of Directors on November 28, 2023.

2. Basis of preparation

These interim condensed consolidated financial

statements for the three-month and nine-month periods ended September 30, 2023, have been prepared under the historic cost convention

and in accordance with IAS 34 "Interim Financial Reporting" and are presented in a format consistent with the consolidated

financial statements under IAS 1 "Presentation of Financial Statements". However, they do not include all of the notes that

would be required in a complete set of financial statements. Thus, this interim financial report should be read in conjunction with the

consolidated financial statements for the year ended December 31, 2022.

Interim financial results are not necessarily

indicative of results anticipated for the full year. The preparation of these unaudited interim condensed consolidated financial statements

made in accordance with IAS 34 requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities

and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and

expenses during the reporting period. Although these estimates are based on management's best knowledge of current events and actions,

actual results ultimately may differ from those estimates. The areas involving a higher degree of judgment which are significant to the

interim condensed consolidated financial statements are disclosed in note 4 to the consolidated financial statements for the year ended

A number of new or amended standards and interpretations

became applicable for financial reporting periods beginning on or after January 1, 2023. The Group noted that the latter did not

have a material impact on the Group's financial position or disclosures made in the interim condensed consolidated financial statements.

Due to rounding, numbers presented throughout

these interim condensed consolidated financial statements may not add up precisely to the totals provided. All ratios and variances are

calculated using the underlying amounts rather than the presented rounded amounts.

Where necessary, comparative figures have been

revised to conform with the current year 2023 presentation.

3. Critical accounting estimates and judgments

The Group makes estimates and assumptions concerning

the future. These estimates and judgments are continually evaluated and are based on historical experience and other factors, including

expectations of future events that are believed to be reasonable under the circumstances. The resulting accounting estimates will, by

definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material

adjustment to the carrying amounts of assets and liabilities or may have had a significant impact on the reported results are disclosed

Addex Therapeutics Unaudited

Interim Condensed Consolidated Financial Statements Notes

The Group's accounts are prepared on a

going concern basis. To date, the Group has financed its cash requirements primarily from share issuances and licensing certain of its

research and development stage products. The Group is a development-stage enterprise and is exposed to all the risks inherent in establishing

a business. The Group expects that its existing cash and cash equivalents, at the issuance date of these unaudited interim condensed

consolidated financial statements, will be sufficient to fund its operations and meet all of its obligations as they fall due until the

first quarter of 2024. These factors individually and collectively indicate that a material uncertainty exists that raise substantial